Ann Thorac Surg 1995;59:844
© 1995 The Society of Thoracic Surgeons
Discussion
DISCUSSION
See also page 835.
DR CAROLYN E. REED (Charleston, SC): I congratulate you on a tremendous amount of work in a very difficult tumor, and I think we all look forward to your work at the National Cancer Institute (NCI) to help us treat a difficult cancer. I have one question for you. I noticed in your abstract that you stated that your cell lines have growth arrest with paclitaxel, and I wonder if you could tell us a little bit more about that because I think all of us are looking for new modalities or new drugs to treat this difficult disease.
DR PASS: I did not present the paclitaxel data because I simply wanted to go over how we set up cell lines. We were interested in paclitaxel because it has been seen to have some responses in non--small cell lung cancers. In all of them, instead of having a nice growth with time, they just sat there and did not grow. At the NCI we now have an ongoing trial with paclitaxel radiation therapy and we also have shown that paclitaxel is a radiation sensitizer.
DR RONALD C. HILL (Morgantown, WV): These are exciting data and I appreciate you bringing them to the Association. Have you looked at abdominal mesotheliomas, and if so, are there any differences?
DR PASS: We also have a program for abdominal mesothelioma, which includes hyperthermic cisplatin. We have grown the mesothelioma cell lines from the abdomen and they look very much like the pleural mesothelioma cell lines.
Related Article
-
Characteristics of Nine Newly Derived Mesothelioma Cell Lines
- Harvey I. Pass, Emily J. Stevens, Herbert Oie, Maria G. Tsokos, Andrea D. Abati, Patricia A. Fetsch, Daphne J. Y. Mew, Helen W. Pogrebniak, and Wilbert J. Matthews
Ann. Thorac. Surg. 1995 59: 835-844.
[Abstract]
[Full Text]
